Bgb-3245
Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
MapKure, LLCPhase 1Active
D
23/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 8/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PANITUMUMAB MapKure, LLC | Phase 1 | CC |
Same molecule, other indications
Bgb-3245 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →